Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esperoct in pediatric severe haemophilia A
NCT01731600Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2013
- Primary completion
- Sep 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 16
01
Overview
Phase 3, open-label, single-arm trial of recombinant human coagulation factor VIII in hemophilia A, sponsored by Novo Nordisk. Primary endpoint: Number of Participants With Inhibitory Antibodies Against Coagulation Factor VIII. Started Feb 2013; status: completed.
02
Drugs
recombinant human coagulation factor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT01731600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01731600.